- Home
- HIMX vs ATRC Comparison
HIMX vs ATRC Comparison
Compare HIMX & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMX
- ATRC
- Stock Information
- Founded
- HIMX 2001
- ATRC 2000
- Country
- HIMX Taiwan
- ATRC United States
- Employees
- HIMX N/A
- ATRC N/A
- Industry
- HIMX Semiconductors
- ATRC Medical/Dental Instruments
- Sector
- HIMX Technology
- ATRC Health Care
- Exchange
- HIMX Nasdaq
- ATRC Nasdaq
- Market Cap
- HIMX N/A
- ATRC 1.1B
- IPO Year
- HIMX 2006
- ATRC 2005
- Fundamental
- Price
- HIMX $10.24
- ATRC $39.84
- Analyst Decision
- HIMX Buy
- ATRC Strong Buy
- Analyst Count
- HIMX 1
- ATRC 9
- Target Price
- HIMX $15.00
- ATRC $43.00
- AVG Volume (30 Days)
- HIMX 5.5M
- ATRC 618.4K
- Earning Date
- HIMX 02-13-2025
- ATRC 02-12-2025
- Dividend Yield
- HIMX 2.87%
- ATRC N/A
- EPS Growth
- HIMX 10.98
- ATRC N/A
- EPS
- HIMX 0.44
- ATRC N/A
- Revenue
- HIMX $897,257,000.00
- ATRC $447,573,000.00
- Revenue This Year
- HIMX $12.75
- ATRC $18.02
- Revenue Next Year
- HIMX N/A
- ATRC $12.93
- P/E Ratio
- HIMX $21.15
- ATRC N/A
- Revenue Growth
- HIMX N/A
- ATRC 17.56
- 52 Week Low
- HIMX $4.80
- ATRC $18.94
- 52 Week High
- HIMX $13.91
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- HIMX 52.38
- ATRC 61.66
- Support Level
- HIMX $9.21
- ATRC $39.71
- Resistance Level
- HIMX $10.52
- ATRC $43.11
- Average True Range (ATR)
- HIMX 1.08
- ATRC 1.86
- MACD
- HIMX -0.06
- ATRC 0.15
- Stochastic Oscillator
- HIMX 32.55
- ATRC 63.10
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.